Alzheimer’s, the new drug is likely to be a therapy for the few

THE FIRST Alzheimer’s drug approved in the last 20 years, Aduhelm, was inevitably welcomed by patients and family members as a real boon: a real hope for a condition hitherto considered irreversible. This is especially true in the United States, where the FDA has approved it with an accelerated procedure. But, unfortunately, there is still a long way to go before it becomes an accessible therapy for all.